Department of Clinical Laboratory, the Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China.
Department of Clinical Laboratory Medicine, the First Affiliated Hospital of Chongqing Medical University, No. 1 Friendship Road, Yuzhong District, Chongqing, 400016, China.
BMC Cancer. 2022 Jan 3;22(1):10. doi: 10.1186/s12885-021-09068-w.
New evidence from clinical and fundamental researches suggests that SNHG7 is involved in the occurrence and development of carcinomas. And the increased levels of SNHG7 are associated with poor prognosis in various kinds of tumors. However, the small sample size was the limitation for the prognostic value of SNHG7 in clinical application. The aim of the present meta-analysis was to conduct a qualitative analysis to explore the prognostic value of SNHG7 in various cancers.
Articles related to the SNHG7 as a prognostic biomarker for cancer patients, were comprehensive searched in several electronic databases. The enrolled articles were qualified via the preferred reporting items for systematic reviews and meta-analysis of observational studies in epidemiology checklists. Additionally, an online database based on The Cancer Genome Atlas (TCGA) was further used to validate our results.
We analyzed 2418 cancer patients that met the specified criteria. The present research indicated that an elevated SNHG7 expression level was significantly associated with unfavorable overall survival (OS) (HR = 2.45, 95% CI: 2.12-2.85, p <0.001). Subgroup analysis showed that high expression levels of SNHG7 were also significantly associated with unfavorable OS in digestive system cancer (HR = 2.31, 95% CI: 1.90-2.80, p <0.001) and non-digestive system cancer (HR = 2.67, 95% CI: 2.12-3.37, p <0.001). Additionally, increased SNHG7 expression was found to be associated with tumor stage and progression (III/IV vs. I/II: HR = 1.76, 95% CI: 1.57-1.98, p <0.001). Furthermore, elevated SNHG7 expression significantly predicted lymph node metastasis (LNM) (HR = 1.98, 95% CI: 1.74-2.26, p <0.001) and distant metastasis (DM) (HR = 2.49, 95% CI: 1.88-3.30, p <0.001) respectively. No significant heterogeneity was observed among these studies. SNHG7 was significantly upregulated in four cancers and the elevated expression of SNHG7 predicted shorter OS in four cancers, worse DFS in five malignancies and worse PFI in five carcinomas based on the validation using the GEPIA on-line analysis tool.
The present analysis suggests that elevated SNHG7 is significantly associated with unfavorable OS, tumor progression, LNM and DM in various carcinomas, and may be served as a promising biomarker to guide therapy for cancer patients.
临床和基础研究的新证据表明，SNHG7 参与了癌的发生和发展。SNHG7 的水平升高与各种肿瘤的预后不良有关。然而，小样本量是 SNHG7 在临床应用中预后价值的局限性。本荟萃分析的目的是进行定性分析，以探讨 SNHG7 在各种癌症中的预后价值。
综合检索了几个电子数据库中与 SNHG7 作为癌症患者预后生物标志物相关的文章。通过流行病学观察研究系统评价和荟萃分析的首选报告项目检查表对纳入的文章进行了质量评估。此外，还进一步使用基于癌症基因组图谱（TCGA）的在线数据库来验证我们的结果。
我们分析了 2418 名符合特定标准的癌症患者。本研究表明，SNHG7 表达水平升高与总生存期（OS）不良显著相关（HR=2.45，95%CI：2.12-2.85，p<0.001）。亚组分析表明，SNHG7 高表达也与消化系统癌症（HR=2.31，95%CI：1.90-2.80，p<0.001）和非消化系统癌症（HR=2.67，95%CI：2.12-3.37，p<0.001）的 OS 不良显著相关。此外，发现 SNHG7 表达增加与肿瘤分期和进展有关（III/IV 期与 I/II 期：HR=1.76，95%CI：1.57-1.98，p<0.001）。此外，SNHG7 高表达显著预测淋巴结转移（LNM）（HR=1.98，95%CI：1.74-2.26，p<0.001）和远处转移（DM）（HR=2.49，95%CI：1.88-3.30，p<0.001）。这些研究之间没有观察到显著的异质性。SNHG7 在四种癌症中明显上调，基于 GEPIA 在线分析工具的验证，SNHG7 的高表达预示着四种癌症的 OS 更差、五种恶性肿瘤的无病生存期（DFS）更差、五种癌的无进展生存期（PFI）更差。
本分析表明，SNHG7 水平升高与各种癌的 OS 不良、肿瘤进展、LNM 和 DM 显著相关，可能成为指导癌症患者治疗的有前途的生物标志物。
